RJA
FLXN

Raymond James & Associates’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Raymond James & Associates’s Portfolio FLXN Stock Details FLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-26,100
Closed -$34K – 3698
2018
Q1 		$34K Buy
26,100
+6,800
+35% +$166K ﹤0.01% 3354
2017
Q4 		$27K Buy
+19,300
New +$473K ﹤0.01% 3328
2017
Q2 		– Sell
-25,700
Closed -$190K – 3463
2017
Q1 		$190K Buy
+25,700
New +$525K ﹤0.01% 2948

Raymond James & Associates's FLXN Position: Q4 2021 in Review

Raymond James & Associates sold out of Flexion Therapeutics, Inc. (FLXN) in Q4 2021, closing a stake of 444,705 shares — an estimated $2.71M sold.

Raymond James & Associates first reported a position in FLXN in Q4 2016 and held it in 20 quarters. The position peaked at $5.23M in Q4 2017. 1 fund tracked by Wall St. Rank holds FLXN as of Q4 2021.

  • Raymond James & Associates reported no remaining Flexion Therapeutics, Inc. position as of Q4 2021 after selling out during the quarter.
  • Raymond James & Associates sold 444,705 Flexion Therapeutics, Inc. shares in Q4 2021, an estimated $2.71M.
  • Raymond James & Associates first reported a position in Flexion Therapeutics, Inc. in Q4 2016 and held it in 20 quarters.
  • Raymond James & Associates's Flexion Therapeutics, Inc. position peaked at $5.23M in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q4 2021.

Based on Raymond James & Associates's 13F filing for Q4 2021, filed 8 Feb 2022.